Kalle Aaltonen1, Arto Heinonen2, Jaana Joensuu2, Pinja Parmanne3, Anna Karjalainen4, Tuire Varjolahti-Lehtinen5, Toini Uutela6, Maija Puurtinen-Vilkki7, Leena Arstila8, Marja Blom2, Tuulikki Sokka9, Dan Nordström10. 1. Department of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014 Helsinki, Finland. Electronic address: kalle.jm.aaltonen@helsinki.fi. 2. Department of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014 Helsinki, Finland. 3. Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland. 4. Department of Medicine, Oulu University Hospital, Oulu, Finland; Institute of Clinical Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland. 5. Department of Medicine, Tampere City Hospital, Tampere, Finland. 6. Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland. 7. Department of Medicine, Turku University Hospital, Turku, Finland. 8. Department of Medicine, Kuopio University Hospital, Kuopio, Finland. 9. Department of Medicine, Jyväskylä Central Hospital, Jyväskylä, Finland; School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland. 10. Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland; Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND AND OBJECTIVES: Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of observational studies on this subject have been published thus far. The aim of this research was to analyze the effectiveness and drug survival of TNF-inhibitors in the treatment of PsA. METHODS: PsA patients identified from the National Register for Biologic Treatment in Finland (ROB-FIN) starting their first, second, or third TNF-inhibitor treatment between 2004 and 2014 were included. Effectiveness was measured using ACR and EULAR response criteria and modeled using ordinal logistic regression. Treatment persistence was analyzed using Kaplan-Meier survival analysis and Cox proportional hazards model. RESULTS: The study comprised 765 patients and 990 TNF-inhibitor treatment courses. EULAR moderate treatment responses at 6 months were achieved by 68% and 37% of the users of the first and the second or the third biologic, respectively. The probabilities of discontinuing the treatment within 12 and 24 months were 20% and 28%, respectively. Adjusted treatment responses to all TNF-inhibitors were similar; however, co-therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) was not associated with better effectiveness. Adalimumab [hazard ratio (HR) = 0.62; 95% confidence interval (CI): 0.44-0.88] was superior to infliximab in drug survival while etanercept (HR = 0.77, 95% CI: 0.55-1.1) and golimumab (HR = 0.75, 95% CI: 0.46-1.2) did not differ from it. Co-medication with csDMARDs did not statistically improve drug survival. CONCLUSION: All available TNF-inhibitors showed similar treatment responses with or without csDMARDs. Adalimumab was associated with better drug survival when compared to infliximab.
BACKGROUND AND OBJECTIVES:Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of observational studies on this subject have been published thus far. The aim of this research was to analyze the effectiveness and drug survival of TNF-inhibitors in the treatment of PsA. METHODS: PsA patients identified from the National Register for Biologic Treatment in Finland (ROB-FIN) starting their first, second, or third TNF-inhibitor treatment between 2004 and 2014 were included. Effectiveness was measured using ACR and EULAR response criteria and modeled using ordinal logistic regression. Treatment persistence was analyzed using Kaplan-Meier survival analysis and Cox proportional hazards model. RESULTS: The study comprised 765 patients and 990 TNF-inhibitor treatment courses. EULAR moderate treatment responses at 6 months were achieved by 68% and 37% of the users of the first and the second or the third biologic, respectively. The probabilities of discontinuing the treatment within 12 and 24 months were 20% and 28%, respectively. Adjusted treatment responses to all TNF-inhibitors were similar; however, co-therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) was not associated with better effectiveness. Adalimumab [hazard ratio (HR) = 0.62; 95% confidence interval (CI): 0.44-0.88] was superior to infliximab in drug survival while etanercept (HR = 0.77, 95% CI: 0.55-1.1) and golimumab (HR = 0.75, 95% CI: 0.46-1.2) did not differ from it. Co-medication with csDMARDs did not statistically improve drug survival. CONCLUSION: All available TNF-inhibitors showed similar treatment responses with or without csDMARDs. Adalimumab was associated with better drug survival when compared to infliximab.
Authors: Gustavo Deza; Jaime Notario; Marta Ferran; Emma Beltrán; Miriam Almirall; Rebeca Alcalá; José Carlos Ruiz-Carrascosa; Ricardo Sánchez; Silvia Pérez; María Luz García-Vivar; Eva Galíndez; Maribel Mora; Jesús Rodríguez; Fernando Gallardo Journal: Rheumatol Int Date: 2018-08-24 Impact factor: 2.631
Authors: Philip J Mease; Neil A Accortt; Sabrina Rebello; Carol J Etzel; Ryan W Harrison; Girish A Aras; Mahdi M F Gharaibeh; Jeffrey D Greenberg; David H Collier Journal: Rheumatol Int Date: 2019-07-18 Impact factor: 2.631
Authors: Katerina Chatzidionysiou; Merete Lund Hetland; Thomas Frisell; Daniela Di Giuseppe; Karin Hellgren; Bente Glintborg; Dan Nordström; Kalle Aaltonen; Minna Rk Törmänen; Eirik Klami Kristianslund; Tore K Kvien; Sella A Provan; Bjorn Björn Guðbjörnsson; Lene Dreyer; Lars Erik Kristensen; Tanja Schjødt Jørgensen; Lennart Jacobsson; Johan Askling Journal: RMD Open Date: 2018-04-12
Authors: Karin Luttropp; Mary Dozier; Nahila Justo; Freddy Cornillie; Sumesh Kachroo; Marinella Govoni; Stina Salomonsson; Christopher M Black; Ahmed Khalifa Journal: BMJ Open Date: 2019-05-28 Impact factor: 2.692
Authors: Michael Ruberson Ribeiro da Silva; Jéssica Barreto Ribeiro Dos Santos; Alessandra Maciel Almeida; Alexander Itria; Adriana Maria Kakehasi; Juliana Alvares Teodoro; Francisco de Assis Acurcio Journal: Future Sci OA Date: 2019-01-18
Authors: Ana F Souza; Michael R Da Silva; Jéssica B Dos Santos; Alessandra M Almeida; Francisco A Acurcio; Juliana Alvares-Teodoro Journal: Pharm Pract (Granada) Date: 2021-05-28